PCSA Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. (PCSA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: July 1, 2026 , by Ng George K .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Ng George K | Chief Executive Officer | Buy | 3,057 | $1.93 | $5.9K | 15,492 | |
| SKIBSTED RUSSELL | Chief Financial Officer | Buy | 3,277 | $1.93 | $6.3K | 16,689 | |
| Young David | Pres. Research & Development | Buy | 2,531 | $1.93 | $4.9K | 21,729 | |
| Guy Wendy | Chief Administrative Officer | Buy | 2,436 | $1.93 | $4.7K | 14,394 | |
| Lin Patrick | Chief Business - Strategy Off | Buy | 2,106 | $1.93 | $4.1K | 13,113 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.